Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia
- 30 June 2003
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 63 (6), 2020-2027
- https://doi.org/10.1046/j.1523-1755.2003.00029.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000
- Pathogenesis of secondary hyperparathyroidismKidney International, 1999
- The hyperparathyroidism of chronic renal failure: A disorder of growthKidney International, 1997
- A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor contentAmerican Journal of Kidney Diseases, 1997
- Regulation of parathyroid cell proliferationCurrent Opinion in Nephrology and Hypertension, 1997
- Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failureAmerican Journal of Kidney Diseases, 1996
- Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.JCI Insight, 1996
- A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemiaAmerican Journal of Kidney Diseases, 1995
- Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.JCI Insight, 1995
- 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremiaKidney International, 1989